tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

KYKOF Stock Latest News

Kyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
The FlyKyowa Kirin downgraded to Sell from Neutral at Goldman Sachs
5h ago
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
PremiumCompany Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Market Implications
2M ago
KYKOF
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
PremiumCompany Announcements
Kyowa Kirin’s New Clinical Trial: A Potential Game-Changer in T-Cell Lymphoma Treatment
2M ago
KYKOF
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema
2M ago
KYKOF
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
PremiumCompany Announcements
Kyowa Kirin’s Promising Phase 2 Study on nAMD Treatment: A Market Game-Changer?
2M ago
KYKOF
Kyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
PremiumCompany AnnouncementsKyowa Kirin’s KK8123 Study: A Potential Game-Changer for X-linked Hypophosphatemia
2M ago
KYKOF
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
Premium
Company Announcements
Kyowa Kirin’s KK3910: A New Hope in Hypertension Treatment?
2M ago
KYKOF
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
Premium
Company Announcements
Kyowa Kirin’s Phase 3 Trial on KK8398 for Achondroplasia: A Potential Game-Changer
2M ago
KYKOF
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KK2845 for Acute Myeloid Leukemia
2M ago
KYKOF
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK2260 Study: A Potential Game-Changer in Cancer Treatment?
2M ago
KYKOF
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
PremiumCompany Announcements
Kyowa Kirin’s KK2269 Study: A Potential Game-Changer in Solid Tumor Treatment?
2M ago
KYKOF
Kura Oncology receives $30M development milestone payment for ziftomenib
PremiumThe Fly
Kura Oncology receives $30M development milestone payment for ziftomenib
2M ago
KURA
Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
PremiumThe FlyKura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
3M ago
KURA
Kyowa Kirin’s Poteligeo Study: A Closer Look at Safety and Efficacy
Premium
Company Announcements
Kyowa Kirin’s Poteligeo Study: A Closer Look at Safety and Efficacy
4M ago
KYKOF
Kyowa Kirin Earnings Call: Mixed Sentiment Amid Growth and Challenges
Premium
Company Announcements
Kyowa Kirin Earnings Call: Mixed Sentiment Amid Growth and Challenges
4M ago
Kyowa Kirin’s Promising Phase 2 Study on DME Treatment: A Market Game-Changer?
PremiumCompany Announcements
Kyowa Kirin’s Promising Phase 2 Study on DME Treatment: A Market Game-Changer?
5M ago
KYKOF
Kyowa Kirin’s KHK4827 Study Completion: A Potential Game-Changer for Systemic Sclerosis Treatment
PremiumCompany Announcements
Kyowa Kirin’s KHK4827 Study Completion: A Potential Game-Changer for Systemic Sclerosis Treatment
5M ago
KYKOF
Kyowa Kirin’s Phase 3 Study on KHK4827 for Systemic Sclerosis: Market Implications
PremiumCompany Announcements
Kyowa Kirin’s Phase 3 Study on KHK4827 for Systemic Sclerosis: Market Implications
5M ago
KYKOF
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema: A Potential Game-Changer
PremiumCompany Announcements
Kyowa Kirin’s Promising Study on KHK4951 for Diabetic Macular Edema: A Potential Game-Changer
6M ago
KYKOF
Kura, Kyowa say ziftomenib abstract accepted for EHA Congress
PremiumThe FlyKura, Kyowa say ziftomenib abstract accepted for EHA Congress
7M ago
KURA
Is KYKOF a Buy, Before Earnings?
Premium
Pre-Earnings
Is KYKOF a Buy, Before Earnings?
11M ago
Nvidia reports Q3 beat, Starbucks explores China partnerships: Morning Buzz
Premium
The Fly
Nvidia reports Q3 beat, Starbucks explores China partnerships: Morning Buzz
1y ago
BA
BJ

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >